Myocardial Infarction (MI) Therapeutics Market Size, Share, Growth Analysis, By Treatment/Drug Type(Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers), By Route of Administration(Oral, Injectable), By Distribution Channel(Offline drug stores (Retail Pharmacies, Hospital Pharmacies), Online drug stores), By Region - Industry Forecast 2024-2031

Myocardial Infarction (MI) Therapeutics Market size was valued at around USD 2.20 billion in 2022 and is expected to rise from USD 2.31 billion in 2023 to reach a value of USD 3.36 billion by 2031, at a CAGR of 4.82% over the forecast period (2024–2031).

The main cause of myocardial infarction, often known as a heart attack, is coronary artery disease, which results in a decreased blood flow to the heart muscles. Myocardial infarction happens when an area of the heart loses oxygen because one of the coronary arteries is blocked. Typically, blockages form as a result of atherosclerotic plaque accumulation on artery walls. The septal, anterior, posterior, lateral, or inferior walls of the left ventricle of the heart are where myocardial infarctions are most often found. Thus, insufficient oxygen results in the death of cardiac tissue and a recognisable chest discomfort in humans, which causes myocardial infarction. Around 17.3 million people worldwide pass away from heart disease each year, with myocardial infarction being the main cause of death, according to the American Heart Association (AHA). This increases the requirement of treatments for myocardial infarction which leads to the growth of the myocardial infarction (MI) therapeutics market.

The growth of the market for myocardial infarction treatment is also due to the rising prevalence of cardiovascular disorders and the growing senior population. The increased frequency of obesity and chronic disorders like diabetes, hypertension, and chronic kidney disease are further reasons driving this market's expansion. Additionally, unhealthy lifestyle habits, excessive alcohol consumption, and drug use—including amphetamine and cocaine use—among the populace are significant risk factors for myocardial infarction. As a result, the market for myocardial infarction treatment and management products is expected to grow in the coming years. According to estimates, the global market for myocardial infarction treatments has the potential to be lucrative and to grow due to the rising popularity of efficient and secure treatment protocols. The market for myocardial infarction treatments may develop as a result of anticipated technology advancements that will create a plethora of chances for detecting specific blockages, monitoring cellular response, and determining hereditary predisposition.

US Myocardial Infarction (MI) Therapeutics Market  is poised to grow at a sustainable CAGR for the next forecast year.